Replies to post #6435 on Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

And it must be said that the dilution is only a part of the story of this drop. The other part is that they violated their assurances that financings
were a thing of the past, AND, they took a clearly understandable and hugely successful business model and blew it up by creating vast uncertainty, muddying the waters about what the future holds. We know what the market feels about uncertainty. Confidence in the current management, and the wisdom of their future plans, formerly very high, is badly shaken. So, that's the story in total. In weeks and months to come, we'll languish hereabouts absent material news, and if the news involves a questionable and expensive acquisition, that will surely open a hole in the earth and sink HALO for a long time. This really sucks.

[biotechinvestor1]

Not so sure about that. Halozyme issued convertible bonds in 2019 (with far worse terms than in 2021) and the stock price went up significantly and consistently for weeks.

There are many other factors involved including overall market, XBI, IBB, etc. But it does not make a lot of sense to think the expected good news (trial milestones) are all baked in but the expected acquisition is not.